Prinaberel

From Wikipedia, the free encyclopedia

Template:Short description Template:Short description Page Template:Infobox drug/styles.css has no content.

Page Module:Infobox/styles.css has no content.

Prinaberel
Lua error in package.lua at line 80: module 'Module:InfoboxImage/data' not found.
Clinical data
ATC codePage Template:Plainlist/styles.css has no content.
  • None
Identifiers
  • (4Z)-2-Fluoro-4-(5-hydroxy-7-vinyl-1,3-benzoxazol-2(3H)-ylidene)-2,5-cyclohexadien-1-one
CAS NumberPage Template:Plainlist/styles.css has no content.
PubChem CIDPage Template:Plainlist/styles.css has no content.
PubChem SIDPage Template:Plainlist/styles.css has no content.
IUPHAR/BPSPage Template:Plainlist/styles.css has no content.
DrugBankPage Template:Plainlist/styles.css has no content.
ChemSpiderPage Template:Plainlist/styles.css has no content.
UNIIPage Template:Plainlist/styles.css has no content.
KEGGPage Template:Plainlist/styles.css has no content.
ChEBIPage Template:Plainlist/styles.css has no content.
ChEMBLPage Template:Plainlist/styles.css has no content.
NIAID ChemDBPage Template:Plainlist/styles.css has no content.
PDB ligandPage Template:Plainlist/styles.css has no content.
CompTox Dashboard (EPA)Page Template:Plainlist/styles.css has no content.
Chemical and physical data
FormulaC15H10FNO3
Molar mass271.247 g·mol−1
3D model (JSmol)Page Template:Plainlist/styles.css has no content.
  • O=C3\C=C/C(=C2/Oc1c(cc(O)cc1N2)\C=C)/C=C3/F
  • InChI=1S/C15H10FNO3/c1-2-8-5-10(18)7-12-14(8)20-15(17-12)9-3-4-13(19)11(16)6-9/h2-7,17-18H,1H2/b15-9-
  • Key:FCXYSEXZEGPLGG-DHDCSXOGSA-N
Data page
Template:Infobox drug/data page link

Prinaberel (INN, USAN) (developmental code names ERB-041, WAY-202041) is a synthetic, nonsteroidal, and highly selective agonist of the ERβ subtype of the estrogen receptor.[1] It is used in scientific research to elucidate the role of the ERβ receptor.[2] Studies have indicated that selective ERβ agonists like prinaberel could be useful in the clinical treatment of a variety of medical conditions including inflammatory bowel disease, rheumatoid arthritis, endometriosis, and sepsis.[3] Accordingly, prinaberel either was or still is under investigation by Wyeth for the treatment of some of these conditions.[4]

See also

References

Page Template:Reflist/styles.css has no content.

  1. ^ Page Module:Citation/CS1/styles.css has no content.Harris HA, Albert LM, Leathurby Y, et al. (October 2003). "Evaluation of an estrogen receptor-beta agonist in animal models of human disease". Endocrinology. 144 (10): 4241–9. doi:10.1210/en.2003-0550. PMID 14500559.
  2. ^ Page Module:Citation/CS1/styles.css has no content.Koehler KF, Helguero LA, Haldosén LA, Warner M, Gustafsson JA (May 2005). "Reflections on the discovery and significance of estrogen receptor beta". Endocrine Reviews. 26 (3): 465–78. doi:10.1210/er.2004-0027. PMID 15857973.
  3. ^ Page Module:Citation/CS1/styles.css has no content.Harris HA (2006). "Preclinical characterization of selective estrogen receptor beta agonists: new insights into their therapeutic potential". Ernst Schering Foundation Symposium Proceedings. 2006/1 (1): 149–61. doi:10.1007/2789_2006_021. ISBN 978-3-540-49547-5. PMID 17824176.
  4. ^ Page Module:Citation/CS1/styles.css has no content."Prinaberel - Wyeth phase change II, USA (endometriosis)". R & D Focus Drug News. 2006-06-05. Archived from the original on 2016-03-07. Retrieved 2012-05-20.

Lua error in package.lua at line 80: module 'Module:Navbox/configuration' not found.

Template:Asbox

Retrieved from "https://cosmopedia.co/index.php?title=Prinaberel&oldid=11133782"